The global CRO where clinical trials run on time
Finding a CRO to deliver your pivotal Phase 2 & 3 clinical trials on time and on budget isn’t easy. Choose the CRO you can trust.
Therapeutic areas
Oncology
Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Ovarian Cancer and other Oncology indications.
Hematology
Multiple Myeloma, Lymphomas, Leukemias and other oncohematological indications.
Rare Diseases
Hemophilia A & B, Von Willebrand Disease, Thrombocytopenia, Polycythemia Vera, Paroxysmal Nocturnal Hemoglobinuria (PNH).
PSI On Point
The PSI Advantage
In 2021, PSI CRO has again received CRO Leadership Awards in five categories, including Compatibility, Expertise, Quality, Reliability, and Capabilities across two respondent groups (Overall and Small Pharma). In the Expertise category, PSI CRO is recognized as a Champion in the Leadership Awards. The CRO Leadership Awards are presented by Life Sciences Leader based on research conducted by ISR reports. The awards recognize CROs that are voted by sponsors to meet or exceed expectations.
Your last patient in is our first priority
PSI has been exceedingly professional and is respected by our site as a great collaborator.
Anthony W. Tolcher, MD, FRCP, FACP
Delivered 24 phase II and III IBD studies